全文获取类型
收费全文 | 61585篇 |
免费 | 3548篇 |
国内免费 | 267篇 |
专业分类
耳鼻咽喉 | 638篇 |
儿科学 | 1646篇 |
妇产科学 | 1378篇 |
基础医学 | 8808篇 |
口腔科学 | 2900篇 |
临床医学 | 5741篇 |
内科学 | 13251篇 |
皮肤病学 | 1650篇 |
神经病学 | 5815篇 |
特种医学 | 1396篇 |
外国民族医学 | 3篇 |
外科学 | 5790篇 |
综合类 | 349篇 |
一般理论 | 32篇 |
预防医学 | 6214篇 |
眼科学 | 1031篇 |
药学 | 4488篇 |
中国医学 | 282篇 |
肿瘤学 | 3988篇 |
出版年
2024年 | 66篇 |
2023年 | 598篇 |
2022年 | 1314篇 |
2021年 | 2428篇 |
2020年 | 1354篇 |
2019年 | 1984篇 |
2018年 | 2318篇 |
2017年 | 1599篇 |
2016年 | 1611篇 |
2015年 | 1962篇 |
2014年 | 2579篇 |
2013年 | 3241篇 |
2012年 | 5011篇 |
2011年 | 5299篇 |
2010年 | 2723篇 |
2009年 | 2312篇 |
2008年 | 3908篇 |
2007年 | 3758篇 |
2006年 | 3448篇 |
2005年 | 3185篇 |
2004年 | 2782篇 |
2003年 | 2456篇 |
2002年 | 2224篇 |
2001年 | 705篇 |
2000年 | 669篇 |
1999年 | 595篇 |
1998年 | 408篇 |
1997年 | 342篇 |
1996年 | 289篇 |
1995年 | 238篇 |
1994年 | 243篇 |
1993年 | 195篇 |
1992年 | 405篇 |
1991年 | 327篇 |
1990年 | 312篇 |
1989年 | 247篇 |
1988年 | 210篇 |
1987年 | 212篇 |
1986年 | 216篇 |
1985年 | 194篇 |
1984年 | 156篇 |
1983年 | 123篇 |
1982年 | 95篇 |
1981年 | 89篇 |
1980年 | 88篇 |
1979年 | 112篇 |
1978年 | 63篇 |
1977年 | 63篇 |
1975年 | 59篇 |
1972年 | 77篇 |
排序方式: 共有10000条查询结果,搜索用时 0 毫秒
81.
Ana Ortega Ph.D. George Dranitsaris M.Sci.Phm. Jeremy Sturgeon M.D. Heather Sutherland M.Sci. Amit Oza M.D. 《Gynecologic oncology》1997,66(3):454-463
The standard treatment for patients with advanced ovarian cancer (AOC) has been cyclophosphamide and cisplatin (CP). Recently, the results of a large randomized comparative trial demonstrated that the combination of paclitaxel and cisplatin (TP) provided a progression-free survival benefit of 5 months. In this study, a cost–utility analysis was performed from a Canadian health care system perspective to estimate the incremental cost-effectiveness of the TP combination. Twelve AOC patients who received treatment with TP were matched for age and disease stage on a 1-to-2 basis with a CP control. Total hospital resource consumption was then collected for all patients. Treatment preferences were estimated from a cohort of 20 patients and 40 healthy female volunteers using the time trade-off technique. The outcomes were then generated through a decision-analytic model. First-line treatment costs with TP were approximately fourfold greater on a per-cycle basis than the CP alternative (Can$1911 vs Can$459). When progression-free survival benefit and patient treatment preferences were incorporated into the analysis, the results of the decision model revealed an incremental cost between Can$12,000 and Can$24,000 per quality-adjusted progression-free year with the TP protocol. Even though the TP combination has a considerably higher drug acquisition cost, the results of the current analysis suggest that this new chemotherapy regimen does provide patients with substantial quality-adjusted progression-free survival benefit at a reasonable cost to the Canadian health care system. 相似文献
82.
BACKGROUND: When and whether early enteral nutrition (EN) benefits critically ill patients is debatable. This prospective clinical audit aimed to evaluate the feasibility of an early EN protocol and to identify factors that may hinder EN delivery in critically ill patients. METHODS: Thirty-six medical patients with severe respiratory failure under invasive ventilation and scheduled to receive early EN, with a length of ICU stay >72 hours, were included. As asserted by the Society of Critical Care Medicine, 8% of patients were priority 1, 72% priority 2, and 20% priority 3 for intensive therapeutic and vital support interventions. RESULTS: Overall, because of gastrointestinal complications, only 39% of the prescribed EN was administered; only 8 (22%) patients did tolerate EN within the first 48 hours after admission and did achieve their minimum nutritional requirements. The most frequent complication (78%) was high volume of gastric residuals followed by abdominal distention (61%), both associated with hemodynamic instability (HI). Gastrointestinal dysfunction was associated with high Acute Physiologic and Chronic Health Evaluation II score (p = .01), total calorie intake (p = .02), total carbohydrate intake (p = .02), HI (p = .03), malnutrition (p = .04), volume of IV saline (p = .04), and concurrent vasoactive drug administration (p = .05). CONCLUSIONS: This audit in extremely severe intensive care patients identified several factors that impair gastrointestinal function and preclude EN at any stage, namely early EN. Nutrition management must take into account concurrent therapies, given their potential interference with nutrition and organ function. 相似文献
83.
84.
85.
An association between the occurrence of antibodies to simian vacuolating virus 40 and bladder cancer in male smokers was found in a case-control study conducted in 200 male patients with bladder cancer and 400 control men. The risk of bladder cancer increases with the years of cigarette smoking. 相似文献
86.
87.
88.
Jesús M. Cesar Ana Vecino Mikel Perez-Vaquero Jos L. Navarro 《European journal of haematology》1993,50(4):234-236
Abstract: Red cell phospholipids (PLs) were assessed in 11 patients with essential thrombocythemia and 5 patients with polycythemia vera. Platelet and plasma PLs were also determined in 10 of these patients, and the results were compared with studies performed in 16 healthy volunteers. The amount of platelet PLs in patients was similar to controls (556 ± 90 nmol/109cells, versus 481 ± 91 nmol/109cells), as was the percentage of the main specimens of these compounds, including phosphatidylserine (11.1 ± 0.8%), which is relevant for platelet procoagulant activity. We did not find differences between red cell PLs of patients (300 ± 60 nmol/109cells), versus controls (289 ± 71 nmol/109cells), and the sphingomyelin/phosphatidylcholine ratio in these cells was the same in both groups (0.75 ± 0.1). Finally, we did not detect any alteration in the amount of plasma PLs specimens. 相似文献
89.
M Oca?a E Del Pozo M Barrios L I Robles J M Baeyens 《European journal of pharmacology》1990,186(2-3):377-378
90.
Daphna Mezad Mordechai Hallak Mahmoud Huleihel Limor Gortzak-Uzan Ana Smolin Moshe Mazor 《Magnesium research》2002,15(3-4):247-252
Our objective was to evaluate the effect of intravenous magnesium sulphate administration to patients with preterm labour on maternal serum and amniotic fluid IL-1beta, IL-6, IL-10 and TNFalpha concentrations. Thirty-six patients at 24-34 weeks of singleton gestation, who presented with contractions (> or = 8 in 60 min) had amniocentesis to rule out intrauterine infection. The patients received intravenous MgSO4 for tocolysis. Twenty-six patients had amniocentesis performed before initiation of MgSO4 (controls) while 10 others had the procedure during tocolytic therapy (study patients). Magnesium, IL-1beta, IL-6, TNFalpha and IL-10 concentrations were measured. Study and control groups were statistically compared using Student t test. Mean magnesium levels were significantly higher in the study group (P < 0.01). There were no significant differences between the cytokines levels in maternal serum and in amniotic fluid between the groups. Our results suggest that the mechanism of magnesium as a tocolytic agent may not be mediated via the examined cytokines. 相似文献